SG11201808713YA - Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier - Google Patents
Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrierInfo
- Publication number
- SG11201808713YA SG11201808713YA SG11201808713YA SG11201808713YA SG11201808713YA SG 11201808713Y A SG11201808713Y A SG 11201808713YA SG 11201808713Y A SG11201808713Y A SG 11201808713YA SG 11201808713Y A SG11201808713Y A SG 11201808713YA SG 11201808713Y A SG11201808713Y A SG 11201808713YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- levodopa
- antioxidant
- pct
- english
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/177262 Al 19 October 2017 (19.10.2017) WIPO I PCT 111111111111110111011111111111010111110111010111011111011111111011111111111110111111 (51) International Patent Classification: A61K 31/198 (2006.01) A61P 27/02 (2006.01) A61K 31/375 (2006.01) A61P 27/10 (2006.01) (21) International Application Number: PCT/AU2017/050310 (22) International Filing Date: 10 April 2017 (10.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 2016901339 11 April 2016 (11.04.2016) AU (71) Applicant: UNIVERSITY OF CANBERRA [AU/AU]; University Drive, Bruce, Australian Capital Territory 2617 (AU). (72) Inventor: ASHBY, Regan; 20 Morris-West Street, Frank- lin, Australian Capital Territory 2913 (AU). (74) Agent: DAVIES COLLISON CAVE PTY LTD; Level 10, 301 Coronation Drive, Milton, Queensland 4064 (AU). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) W O 20 17 / 177 26 2 Al (54) Title: OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRI- ER (57) : Disclosed are compositions comprising levodopa and an antioxidant for inhibiting the development or progression of visual disorders inclusive of visual disorders associated with diabetic retinopathy or Parkinson's disease, and myopia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016901339A AU2016901339A0 (en) | 2016-04-11 | Compositions and methods of use | |
| PCT/AU2017/050310 WO2017177262A1 (en) | 2016-04-11 | 2017-04-10 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808713YA true SG11201808713YA (en) | 2018-11-29 |
Family
ID=60041247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808713YA SG11201808713YA (en) | 2016-04-11 | 2017-04-10 | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10874629B2 (en) |
| EP (1) | EP3442516B1 (en) |
| JP (2) | JP7095873B2 (en) |
| KR (2) | KR102578476B1 (en) |
| CN (2) | CN121370859A (en) |
| AU (2) | AU2017250002B2 (en) |
| CA (1) | CA3019178A1 (en) |
| IL (1) | IL262294A (en) |
| MY (1) | MY190011A (en) |
| SG (1) | SG11201808713YA (en) |
| TW (1) | TWI793072B (en) |
| WO (1) | WO2017177262A1 (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017250002B2 (en) | 2016-04-11 | 2022-12-22 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
| EP3600306A4 (en) * | 2017-03-23 | 2020-12-02 | Singapore Health Services Pte Ltd | MEANS FOR THE PREVENTION OF MYOPIA, TREATMENT OF MYOPIA AND / OR PREVENTION OF THE PROGRESSION OF MYOPIA WITH TIOTROPIA AS THE ACTIVE SUBSTANCE |
| IT201800005599A1 (en) * | 2018-05-22 | 2019-11-22 | Soft contact lens | |
| EP3849533A4 (en) * | 2018-09-13 | 2022-06-22 | University of Canberra | INHIBITION PROCESSES |
| JP7699426B2 (en) * | 2018-11-30 | 2025-06-27 | ロート製薬株式会社 | Ophthalmic composition for protecting cells from photodamage |
| JP7407462B2 (en) * | 2019-03-26 | 2024-01-04 | ウィンサンター・インコーポレイテッド | Topical preparations for the treatment of peripheral neuropathy |
| WO2021021922A1 (en) | 2019-07-30 | 2021-02-04 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating fibrotic pathologies |
| JP7373794B2 (en) * | 2019-11-15 | 2023-11-06 | デンカ株式会社 | Liquid preparation containing gallic acid or gallic acid binding compound |
| JP7506371B2 (en) * | 2020-01-20 | 2024-06-26 | 国立大学法人浜松医科大学 | Dopamine depletion inhibitors |
| JP7513981B2 (en) | 2020-08-31 | 2024-07-10 | デンカ株式会社 | Sulfite-containing liquid |
| EP4284507A4 (en) * | 2021-01-29 | 2025-01-08 | Mayo Foundation for Medical Education and Research | METHODS FOR THE TREATMENT OF FIBROTIC EYE DISEASES |
| KR102589130B1 (en) * | 2021-03-24 | 2023-10-13 | 삼진제약주식회사 | An ophthalmic composition inhibiting occurrence of N-oxo pyridine compound for preventing or treating eye disease |
| WO2023282269A1 (en) * | 2021-07-08 | 2023-01-12 | 協和ファーマケミカル株式会社 | Prophylactic or therapeutic drug for parkinson's disease |
| US20230277521A1 (en) * | 2022-03-07 | 2023-09-07 | Harrow Ip, Llc | Extended-release pharmaceutical compositions for treating eye conditions |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5385939A (en) | 1993-04-30 | 1995-01-31 | The Trustees Of The University Of Pennsylvania | GABA-ergic modulation of eye growth |
| EP0834308A1 (en) | 1996-09-30 | 1998-04-08 | LG Chemical Limited | Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin |
| EP1526858A2 (en) | 2002-06-28 | 2005-05-04 | Novartis AG | Use of gaba-c receptor antagonists for the treatment of myopia |
| US20040220270A1 (en) * | 2003-03-07 | 2004-11-04 | The Jackson Laboratory | Methods and composition of treating glaucoma by modulating tyrosinase/L-DOPA pathway |
| CN1569219A (en) * | 2003-07-14 | 2005-01-26 | 许建文 | Eye drop for treating amblyopia and its preparing process |
| ATE495739T1 (en) | 2003-08-29 | 2011-02-15 | Transform Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING LEVODOPA AND CARBIDOPA |
| SE0401842D0 (en) * | 2004-07-12 | 2004-07-12 | Dizlin Medical Design Ab | Infusion and injection solution of levodopa |
| CN100998586A (en) * | 2007-01-05 | 2007-07-18 | 蒋伟哲 | L-dopa methyl ester eye preparation preparing method and use thereof |
| JP5582535B2 (en) | 2007-06-29 | 2014-09-03 | クラレンス ピーティーワイ エルティーディー | Treatment or prevention of neurological or neuropsychiatric disorders by eye drops |
| EP2300015A4 (en) * | 2008-03-12 | 2011-06-29 | Univ Emory | USE OF GABAA RECEPTOR ANTAGONISTS TO TREAT EXCESSIVE SOMNOLENCE AND DISORDERS ASSOCIATED WITH EXCESSIVE SOMNOLENCE |
| DK3192500T3 (en) * | 2009-05-19 | 2020-12-21 | Neuroderm Ltd | COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA-DECARBOXYLASE INHIBITORS |
| US8470784B2 (en) | 2009-08-24 | 2013-06-25 | Stealth Peptides International, Inc. | Methods and compositions for preventing or treating ophthalmic conditions |
| US9827250B2 (en) | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| WO2015009533A1 (en) * | 2013-07-16 | 2015-01-22 | Allergan, Inc. | Gabaa receptor antagonists affecting ganglion cell function and visual function |
| US20160317474A1 (en) | 2013-12-18 | 2016-11-03 | Emory University | Managing Visual Dysfunction or Loss of Vision for Diabetic Subjects |
| US9421199B2 (en) * | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| EP3188725B1 (en) | 2014-09-04 | 2020-10-28 | Lobsor Pharmaceuticals Aktiebolag | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
| BR112017014016A2 (en) | 2014-12-29 | 2018-01-02 | Orasis Medical Inc | intraocular pressure reduction method; and, pharmaceutical composition. |
| AU2017250002B2 (en) | 2016-04-11 | 2022-12-22 | University Of Canberra | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier |
-
2017
- 2017-04-10 AU AU2017250002A patent/AU2017250002B2/en active Active
- 2017-04-10 CN CN202511479279.0A patent/CN121370859A/en active Pending
- 2017-04-10 TW TW106111880A patent/TWI793072B/en active
- 2017-04-10 KR KR1020227028216A patent/KR102578476B1/en active Active
- 2017-04-10 CA CA3019178A patent/CA3019178A1/en active Pending
- 2017-04-10 JP JP2018553929A patent/JP7095873B2/en active Active
- 2017-04-10 SG SG11201808713YA patent/SG11201808713YA/en unknown
- 2017-04-10 MY MYPI2018703517A patent/MY190011A/en unknown
- 2017-04-10 US US16/092,291 patent/US10874629B2/en active Active
- 2017-04-10 CN CN201780034347.XA patent/CN109310658A/en active Pending
- 2017-04-10 KR KR1020187031409A patent/KR102434254B1/en active Active
- 2017-04-10 WO PCT/AU2017/050310 patent/WO2017177262A1/en not_active Ceased
- 2017-04-10 EP EP17781629.5A patent/EP3442516B1/en active Active
-
2018
- 2018-10-11 IL IL262294A patent/IL262294A/en unknown
-
2020
- 2020-11-24 US US17/103,709 patent/US11890266B2/en active Active
-
2022
- 2022-06-13 JP JP2022094850A patent/JP2022116357A/en active Pending
-
2023
- 2023-03-17 AU AU2023201671A patent/AU2023201671B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP7095873B2 (en) | 2022-07-05 |
| US10874629B2 (en) | 2020-12-29 |
| AU2017250002B2 (en) | 2022-12-22 |
| KR102578476B1 (en) | 2023-09-13 |
| CN109310658A (en) | 2019-02-05 |
| EP3442516B1 (en) | 2025-11-12 |
| JP2022116357A (en) | 2022-08-09 |
| WO2017177262A1 (en) | 2017-10-19 |
| US11890266B2 (en) | 2024-02-06 |
| EP3442516A4 (en) | 2019-12-18 |
| KR20220119521A (en) | 2022-08-29 |
| MY190011A (en) | 2022-03-22 |
| AU2017250002A1 (en) | 2018-10-18 |
| IL262294A (en) | 2018-11-29 |
| JP2019511537A (en) | 2019-04-25 |
| KR20180128473A (en) | 2018-12-03 |
| TW201740931A (en) | 2017-12-01 |
| KR102434254B1 (en) | 2022-08-18 |
| CN121370859A (en) | 2026-01-23 |
| EP3442516A1 (en) | 2019-02-20 |
| US20210077443A1 (en) | 2021-03-18 |
| AU2023201671B2 (en) | 2025-01-02 |
| CA3019178A1 (en) | 2017-10-19 |
| US20190151270A1 (en) | 2019-05-23 |
| AU2023201671A1 (en) | 2023-04-13 |
| TWI793072B (en) | 2023-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201804770QA (en) | Method and arrangement for recovery of salt | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201903153PA (en) | Metal recovery process | |
| SG11201806267QA (en) | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201805001UA (en) | Method of treating influenza a | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201900123TA (en) | Compositions and methods for treating frontotemporal dementia | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201906479SA (en) | Single-use expandable liquid container and blank | |
| SG11201806157WA (en) | Method and pharmaceutical composition for treatment of neurodegeneration |